Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Zymeworks BC Inc chart...

About the Company

zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.

Exchange

NASDAQ

Website

https://www.zymeworks.com/

$28M

Total Revenue

335

Employees

$758M

Market Capitalization

-5.17

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ZYME News

Q4 2023 Zymeworks Inc Earnings Call

11d ago, source:

Paul Moore; Chief Scientific Officer; Zymeworks BC Inc Ken Galbraith; Chairman of the Board, President & CEO; Zymeworks BC Inc Stephen Willey; Analyst; Stifel Nicolaus and Company, Incorporated Yigal ...

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

12d ago, source:

Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments ...

Zymeworks Inc Announces Board Appointments and Resignation

1mon ago, source: TipRanks on MSN

Zymeworks Inc (ZYME) has released an update to notify the public and investors about its officers. Zymeworks Inc. has announced the appointment of Dr. Alessandra Cesano to its board as a Class I ...

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

14d ago, source:

Zymeworks has a strong financial position, with a robust liquidity position and a cash runway that extends into 2027. Learn ...

Vancouver readies for its position as a global pharma capital as B.C.'s biotech boom takes off

7d ago, source:

Vancouver’s life sciences scene dates to the first biotech boom in the early 1980s. Toronto and Montreal also produced ...

ZYME Apr 2024 17.500 call

13d ago, source: Yahoo Finance

VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

ZYME Oct 2024 15.000 call

13d ago, source: Yahoo Finance

VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates

12d ago, source: Zacks.com on MSN

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to earnings of $4.65 per share a year ago. These figures ...

Buy Rating Affirmed for Zymeworks Amid Positive HERIZON Study Outlook and Robust Commercial Prospects of Zanidatamab

6d ago, source:

In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Zymeworks (ZYME – Research Report), with a ...

Zymeworks Inc.: Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

12d ago, source: Finanznachrichten

British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...